Viewray Inc (NASDAQ:VRAY) Announces That Its MRIdian Linac System Used To Treat Patients For The First Time

Viewray Inc (NASDAQ:VRAY) has announced that some cancer patients have been put under treatment using its MRIdian Linac System, making them the first cancer patients to benefit from it.

Story continues below

The company revealed that group of cancer patients to be treated using the MRIdian Linac System were the first cancer patients in history to benefit from the technology. They were reportedly treated at the Henry Ford Health System in Metro Detroit. The system is the only MRI-guided radiation therapy system in the world that has been approved by the FDA. It is the second generation version that improves on the pioneer system that was used to treat 1,500 patients.

“MRIdian offers us the ability to finally see where the patient’s tumor is located in real time using MRI imaging so we know what changes are taking place inside the body and can make the necessary adjustments in real time,” stated Dr. Benjamin Movsas, the head of Radiation Oncology at the Henry Ford Cancer Institute.

Dr. Movsas further described the MRIdian Linac System as a precision radiation system and also pointed out that it allows the physicians to carry out targeted therapy for every individual patient. He believes that the system is a revolutionary step towards changing how radiation is used to treat cancer. Health practitioners in the MRIdian Linac clinical program at Henry Ford have particularly been interested in taking advantage of the adaptive capabilities of the system. this includes the ability to change the degree of radiation to match the changes in the patient’s body as the treatment progresses.

ViewRay CEO, Chris Raanes stated that the MRIdian Linac System also represents new hope to cancer patients. He also stated that his company was excited to be teaming up with the Henry Ford Institute. This is especially because it has a strong reputation and is well known for innovative cancer treatments and clinical excellence. Both ViewRay and the Henry Ford Institute aim to set new standards for cancer treatment.

ViewRay stock closed the latest trading session on Thursday at $5.60 following an 8.20 percent drop in the value of the stock compared to the previous close.

An ad to help with our costs